Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo

Journal of Cancer Research and Clinical Oncology

Volumn 122, Issue 5, 1996, Pages 307-312

  Schröder, Jan ^a   Esteban, Mauricio ^a   Müller, Mark R ^a   Kasimir Bauer, Sabine ^a   Bamberger, Uwe ^b   Heckel, Armin ^b   Seeber, Siegfried ^a   Scheulen, Max E ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Acute myeloid leukemia; BIBW22BS; Chemosensitizer; Multidrug resistance; P glycoprotein

Indexed keywords

BIBW22BS; CYTARABINE; DEXNIGULDIPINE; DOXORUBICIN; GLYCOPROTEIN P; IDARUBICIN; PHENYLPTERIDINE DERIVATIVE; RHODAMINE 123; UNCLASSIFIED DRUG; VERAPAMIL;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTIGENS, CD34; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOCYTIC, ACUTE; MORPHOLINES; RHODAMINE 123; RHODAMINES; TRIAMTERENE;

EID: 0029966455     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01261408     Document Type: Article

References (43)

1. Baer MR, Bloomfield CD (1991) Multidrug resistance in acute myeloid leukemia. J Natl Cancer Inst 83: 663-665
2. Beck WT, Mueller TJ, Tanzer LR (1979) Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 39: 2070-2076
3. Berman E, Heller G, Santorsa J, McKenzie S, Gee, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Reich L, Mayer K, Keefe D, Trainer K, Schluger A, Penenberg D, Raymond V, O'Reilly R, Jhanwar S, Young C, Clarkson B (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77: 1666-1674
4. Biedler JL, Riehm H (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross resistance, radioautographic and cytogenetic studies. Cancer Res 30: 1174-1184
5. + acute myeloid leukemia cells. Blood 82: 3157-3162
6. Bradley G, Jurunka PF, Ling V (1988) Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87-128
7. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute non lymphoblastic leukemia cells at diagnosis. Blood 79: 473-476
8. Chen HX, Bamberger U, Heckel A, Guo X, Cheng YC (1993) BIBW22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport. Cancer Res 53: 1974-1977
9. Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang J, Fojo AT (1990) Characterization of Adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 265: 10073-10080
10. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods WG (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8: 813-819
11. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654
12. Doyle A, Ross D, Fojo A, Kaufmann S, Lee E, Sridhara R, Schiffer C (1993) Expression of a 95 kDa membrane protein is associated with low daunorubicin retention in leukemic blast cells. Proc Am Soc Clin Oncol 12: 302
13. Flasshove M, Scheulen ME, Meusers P, Höffken K, Skorzec M, Käding J, Schoch C, Brittinger G, Seeber S (1992) Phase II study of cytosine arabinoside and idarubicin (AIDA) in acute myelogenous leukemia including cellular and intranuclear pharmacokinetics of idarubicin. Proc Am Soc Clin Oncol 11: 267
14. Fojo A, Akiyama S, Gottesman MM, Pastan I (1985) Reduced drug accumulation in multiple-drug-resistance human KB carcinoma cell lines. Cancer Res 45: 3002-3007
15. Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199
16. Ford JM, Prozialeck WC, Hait WN (1989) Structural feature determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 35: 105-115
17. Jansen WJM, Pinedo HM, Kuiper CM, Lincke C, Bamberger U, Heckel A, Boven E (1994) Biochemical modulation of "classical" multidrug resistance by BIBW22BS, a potent derivative of dipyridamole. Ann Oncol 5: 733-739
18. Kaye SB (1990) Reversal of multidrug resistance. Cancer Treat Rev 17 [Suppl A]: 37-43
19. Kuwazuru Y, Yoshimura A, Hanada S, Utsunomiya A, Makino T, Ishibashi K, Kodama M, Iwahashi M, Arima T, Akiyama S (1990) Expression of the multidrug transporter P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer 66: 868-873
20. Manson JM, Guerriera FJ, Brown T, San Sebastian J (1986) Lack of in vivo mutagenicity and testicular toxicity of triamterene in mice. Fundam Appl Toxicol 7: 533-546
21. Marie J-P, Zittoun R, Sikic BI (1991) Multidrug resistance (mdr1) gene expression in adult acute leukemias correlations with treatment outcome and in vitro drug sensitivity. Blood 78: 586-592
22. McLeod HL (1994) Clinical reversal of multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction? Eur J Cancer 30A: 2039-2041
23. r 170,000 P-glycoprotein in multidrug-resistant human tumor cells. Cancer Res 49: 3209-3214
24. Morrow CS, Cowan KH (1988) Mechanisms and clinical significance of multidrug resistance. Oncology 2: 55
25. Müller MR, Lennartz K, Nowrousian MR, Dux R, Tsuruo T, Rajewsky MF, Seeber S (1994) Improved flow-cytometric detection of low P-glycoprotein expression in leukemic blasts by histogram subtraction analysis. Cytometry 15: 64-72
26. Nooter K, Sonneveld P (1994) Clinical relevance of P-glycoprotein expression in haematological malignancies. Leukemia Res 18: 233-243
27. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H, Lechner K (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83: 708-712
28. Ross DD (1991) Cellular and pharmacologic aspects of drug resistance in acute myeloid leukemia. Curr Opin Oncol 3: 21-29
29. Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL, Felsted RL (1987) Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 262: 7884-7888
30. Sato H, Gottesman MM, Goldstein LJ, Pastan I, Block AM, Sandberg AA, Preisler HD (1990) Expression of multidrug resistence gene in myeloid leukemias. Leuk Res 14: 11-21
31. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53: 1475-1479
32. Scheulen ME, Müller M, Schröder J, Wermes R, Schütte J, Skorzec M, Käding J, Meusers P, Brittinger G, Seeber S (1994) Correlation of cellular pharmacokinetics of idarubicin and idarubicinol, P-glycoprotein expression and response in patients with acute myeloid leukemia. Proc Am Assoc Cancer Res 35: 428
33. Scheulen ME, Meusers P, Schröder J, Uppenkamp M, Müller M, Reiter WW, Weimar C, Rathgeb F, Brittinger G, Seeber S (1995) Phase I/II trial of additive dexniguldipine in acute myeloid leukemia refractory to previous daunorubicin and high-dose cytarabine. Proc Am Assoc Cancer Res 36: 203
34. Schott B, Robert J (1989) Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochem Pharmacol 38: 4069-4074
35. Schröder J, Scheulen ME, Kellner R, Seeber S (1993) In vitro modulation of multidrug resistance by dexniguldipine and verapamil in blasts of de novo or relapsed or persistant AML. Ann Hematol 67 [Suppl]: 441
36. Schröder J, Esteban M, Skubatz M, Scheulen M, Meusers P, Brittinger G, Seeber S (1994) Effects of MDR-modulators on the efflux of idarubicinol from blasts of acute myeloid leukemia ex vivo. Onkologie 17 [Suppl 2]: 539
37. Selleri C, Notaro R, Catalano L, Fontana R, Del Vecchio L, Rotoli B (1992) Prognostic irrelevance of CD34 in acute myeloid leukemia. Br J Haematol 82: 479-482
38. Shalinsky DR, Andreeff M, Howell SB (1990) Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro. Cancer Res 50: 7537-7543
39. Solary E, Bidan JM, Calvo F, Chauffert B, Caillot D, Mugneret F, Gauville C, Tsuruo T, Carli PM, Guy H (1991) P-glycoprotein expression and in vitro revision of doxorubicin resistence by verapamil in clinical specimens from acute leukemia and myeloma. Leukemia 5: 592-597
40. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistence in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972
41. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartulucci AA, Omura GA, Gerber MC, Banks PLC (1992) A phase III trials comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol 10: 1103-1111
42. Wiernik PH, Banks PLC, Case DC Jr, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck PE, Weitberg AB (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79: 313-319
43. Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM, Pastan I (1986) Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive B cells: effects of verapamil and other drugs. Cancer Res 46: 5941-5946